GlobalData has estimated that the global Crohn’s Disease therapeutics market was worth $4.4 billion in 2012
GlobalData estimates that the global GVHD therapeutics market was worth $261.6m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.3% to reach $615.1m by 2018.
Bell Potter has previously noted (Feb 2014) in one of their research reports that GVHD could be a US$300 - $600m and Crohns Disease a US$2.4bn market. In Bell Potters 12 month price target (approx. $9 +), Prochymal has not been factored into their valuation and noted as such -
Based on recent 29/4/14 ASX release ..and CNBC interviews (all posted before) SI quite excited by the potential of Prochymal...in fact MSB's evaluation of the Osiris data at the time , was a major reason why they outlaid $50M + in acquiring their MSC technology.
On 28/5/2014 ASX release about MSB also accelerating there manufacturing plans in Singapore also made reference to Prochymal.
Please DYOR and GLTAH.
- Forums
- ASX - By Stock
- MSB
- Prochymal
Prochymal, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B |
Open | High | Low | Value | Volume |
$1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 280000 | $1.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.07 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 280000 | 1.065 |
5 | 149799 | 1.060 |
9 | 124023 | 1.055 |
14 | 191984 | 1.050 |
8 | 134232 | 1.045 |
Price($) | Vol. | No. |
---|---|---|
1.070 | 2000 | 1 |
1.075 | 19000 | 2 |
1.080 | 48905 | 3 |
1.085 | 28905 | 1 |
1.090 | 61845 | 5 |
Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |